Will we need lymph node dissection at all in the future?

abstract：BACKGROUND:Spontaneous rib fractures (SRFs) are defined as fractures without apparent blunt force trauma. This study evaluated the incidence and risk factors of SRFs after treatment of patients with breast cancer based on bone scans. In addition, we analyzed radiation-associated SRFs and identified radiotherapy (RT) fa...

journal_title：Clinical breast cancer

authors： Kim DW,Kim JS,Kim K,Shin KH

更新日期：2020-07-23 00:00:00

abstract：BACKGROUND:Most investigations have compared triple-negative breast cancer (TNBC) to non-TNBC to elucidate clinical or epidemiologic differences between subtypes. We examined a contemporary cohort of patients with primary TNBC by detection and age at diagnosis within a population-based breast screening program to exami...

journal_title：Clinical breast cancer

authors： Rayson D,Payne JI,Michael JCR,Tsuruda KM,Abdolell M,Barnes PJ

更新日期：2018-10-01 00:00:00

abstract：:In addition to classical clinicopathologic factors, such as hormone receptor positivity, human epidermal growth factor receptor 2 (HER2) status, and tumor size, grade, and lymph node status, a number of commercially available genomic tests may be used to help inform treatment decisions for early breast cancer patients...

journal_title：Clinical breast cancer

authors： Kittaneh M,Badve S,Caldera H,Coleman R,Goetz MP,Mahtani R,Mamounas E,Kalinsky K,Lower E,Pegram M,Press MF,Rugo HS,Schwartzberg L,Traina T,Vogel C

更新日期：2020-06-01 00:00:00

abstract：:Over the past 30 years there has been an increased use of neoadjuvant (or primary) chemotherapy for treating patients with breast cancer. However, while it is clear that chemotherapy given in the adjuvant setting after surgery does prolong patients' overall and disease-free survival, the evidence that chemotherapy in ...

journal_title：Clinical breast cancer

authors： Heys SD,Hutcheon AW,Sarkar TK,Ogston KN,Miller ID,Payne S,Smith I,Walker LG,Eremin O,Aberdeen Breast Group.

更新日期：2002-10-01 00:00:00

abstract：BACKGROUND:Luminal-type breast cancers are the most abundant subtype. Endocrine therapies targeting estrogen receptor (ER) or estradiol (E2) synthesis have achieved marked improvement in disease-free and overall survival of ER-positive cancers. However, approximately one-third of these cancers are poorly responsive to ...

journal_title：Clinical breast cancer

authors： Ito T,Sato N,Yamaguchi Y,Tazawa C,Moriya T,Hirakawa H,Hayashi S

更新日期：2015-04-01 00:00:00

abstract：BACKGROUND:Nanoparticle albumin-bound paclitaxel (nab-P) and bevacizumab have each demonstrated efficacy in patients with MBC. This trial was designed to further develop nab-P by evaluating its efficacy and safety using every 3 weeks (q3w), every 2 weeks (q2w), or weekly scheduling in combination with bevacizumab as fi...

journal_title：Clinical breast cancer

authors： Seidman AD,Conlin AK,Bach A,Moynahan ME,Lake D,Forero A,Wright GS,Hackney MH,Clawson A,Norton L,Hudis CA

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS:Patients received bortezomib...

journal_title：Clinical breast cancer

authors： Irvin WJ Jr,Orlowski RZ,Chiu WK,Carey LA,Collichio FA,Bernard PS,Stijleman IJ,Perou C,Ivanova A,Dees EC

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:Brain metastasis (BM) is a life-threatening event in breast cancer patients. Identifying patients at a high risk for BM can help to adopt screening programs and test preventive interventions. We tried to identify the incidence of BM in different stages and subtypes of breast cancer. PATIENTS AND METHODS:We ...

journal_title：Clinical breast cancer

authors： Azim HA,Abdel-Malek R,Kassem L

更新日期：2018-04-01 00:00:00

abstract：:More than 220,000 women will be diagnosed with breast cancer this year, and approximately 75% of these women will be long-term survivors of this disease. Survival has improved largely because of advances in adjuvant hormone therapy and chemotherapy, as well as early detection strategies. Because most women will receiv...

journal_title：Clinical breast cancer

authors： Rugo HS

更新日期：2007-07-01 00:00:00

abstract：:The sequential use of a doxorubicin combination followed by paclitaxel has been reported to improve disease-free and overall survival in patients with node-positive breast cancer beyond that obtained with doxorubicin/cyclophosphamide combinations. Epirubicin is associated with less cardiotoxicity than doxorubicin and ...

journal_title：Clinical breast cancer

authors： Perez EA

更新日期：2000-09-01 00:00:00

abstract：BACKGROUND:The adoption of hypofractionated radiotherapy (HFRT) into clinical practice varies widely despite randomized trials and guidelines supporting its equivalence to conventional fractionated radiotherapy (CFRT) for certain patient populations. We assessed the use of HFRT at a single institution from 2011 to 2018...

journal_title：Clinical breast cancer

authors： Lam E,Chan S,Karam I,Lee J,Wong G,Zhang L,Vesprini D,Wronski M,Chin L,Razvi Y,McKenzie E,Rakovitch E,Chow E

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:It has been determined that axillary lymph node dissection after the detection of limited axillary lymph node metastasis does not improve the prognosis of patients with breast cancer. Thus, a need exists for less-invasive axillary surgery. However, it remains unclear whether a predictive model based on preop...

journal_title：Clinical breast cancer

authors： Murata T,Watase C,Shiino S,Jimbo K,Iwamoto E,Yoshida M,Takayama S,Suto A

更新日期：2020-11-17 00:00:00

abstract：:During the past decade, improvements in treatment-planning tools, computer and imaging technologies, and new therapeutic modalities have allowed radiation to be delivered in a conformal fashion while minimizing treatment toxicity. It is important that physicians involved in breast cancer treatment recognize the numero...

journal_title：Clinical breast cancer

authors： Frank SJ,McNeese MD,Strom EA,Perkins G,Salehpour M,Schechter N,Buchholz TA

更新日期：2004-02-01 00:00:00

abstract：UNLABELLED:This is a retrospective study on 40 breast cancer patients, of which 20 have bone metastases, 10 have visceral metastases, and 10 have no evidence of disease, aimed at evaluating the role of CXCR4 and the RANK/RANKL/OPG system to predict bone metastases. CXCR4 expression, alone or in combination with RANK, i...

journal_title：Clinical breast cancer

authors： Ibrahim T,Sacanna E,Gaudio M,Mercatali L,Scarpi E,Zoli W,Serra P,Ricci R,Serra L,Kang Y,Amadori D

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Adjuvant trastuzumab improves relapse-free survival in HER2-overexpressing breast cancer but is associated with cardiac toxicity. This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acute and chronic cardiac toxicity of trastuzumab given with weekly p...

journal_title：Clinical breast cancer

authors： Kelly H,Kimmick G,Dees EC,Collichio F,Gatti L,Sawyer L,Ivanova A,Dressler L,Graham ML,Carey LA

更新日期：2006-08-01 00:00:00

abstract：:The potential for cardiac toxicity in association with targeted biologic agents was first observed with trastuzumab, a monoclonal antibody that targets the ErbB2/HER2 receptor. In the pivotal trial of trastuzumab in ErbB2-positive metastatic cancer, an increased incidence of serious cardiac events was observed, partic...

journal_title：Clinical breast cancer

authors： Perez EA

更新日期：2008-03-01 00:00:00

abstract：:Currently, the interest in cognitive functioning following chemotherapy is rapidly expanding as is reflected in a growing number of published studies on this topic. Although most studies are indicative of cognitive deficits after chemotherapy, definite conclusions on the role of chemotherapy on cognitive function can ...

journal_title：Clinical breast cancer

authors： Schagen SB,Muller MJ,Boogerd W,Van Dam FS

更新日期：2002-12-01 00:00:00

abstract：:Chemotherapeutic agents that disrupt the assembly or disassembly of microtubules, including paclitaxel and docetaxel, are among the most commonly prescribed anticancer therapies. However, the utility of taxane-based therapy is limited principally by problems with formulation, slow administration, cumulative neurotoxic...

journal_title：Clinical breast cancer

authors： Andreopoulou E,Muggia F

更新日期：2008-03-01 00:00:00

abstract：:Breast cancer stem cells (BCSCs), characterized by the CD44(+)/CD24(-/low) marker, are attributed with features that are demonstrated by the disease itself, such as growth of tumor, recurrence, metastases, and multiple drug resistance. This review concerns the emergence and expediency of BCSCs in treating relapse and ...

journal_title：Clinical breast cancer

authors： Gangopadhyay S,Nandy A,Hor P,Mukhopadhyay A

更新日期：2013-02-01 00:00:00

abstract：BACKGROUND:Single-frequency bioelectrical impedance (BI) has been used to measure extracellular fluid in the upper limbs. The purpose of the study was to evaluate BI's ability to detect and monitor upper limb changes in based upon the extent of various treatments and to assess its practicality. METHODS:Patients with n...

journal_title：Clinical breast cancer

authors： Vicini F,Shah C,Lyden M,Whitworth P

更新日期：2012-04-01 00:00:00

abstract：:Breast cancer is one of the most commonly diagnosed types of cancer in women. Its pathogenesis involves genetic, hormonal, and environmental factors. A large body of evidence indicates that physical activity has positive effects on every aspect of breast cancer evolution, including prevention, medical treatment, and a...

journal_title：Clinical breast cancer

authors： Adraskela K,Veisaki E,Koutsilieris M,Philippou A

更新日期：2017-10-01 00:00:00

abstract：BACKGROUND:Nanosomal docetaxel lipid suspension formulation was developed to eliminate ethanol and polysorbate 80 from the currently used docetaxel (Taxotere) drug for treatment of cancer patients. NDLS clinical safety and efficacy was evaluated and compared with Taxotere at 75 mg/m(2) in metastatic breast cancer patie...

journal_title：Clinical breast cancer

authors： Ahmad A,Sheikh S,Taran R,Srivastav SP,Prasad K,Rajappa SJ,Kumar V,Gopichand M,Paithankar M,Sharma M,Rane RC,Ahmad I

更新日期：2014-06-01 00:00:00

abstract：BACKGROUND:Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2(+)) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotox...

journal_title：Clinical breast cancer

authors： Gómez HL,Neciosup S,Tosello C,Mano M,Bines J,Ismael G,Santi PX,Pinczowski H,Nerón Y,Fanelli M,Fein L,Sampaio C,Lerzo G,Capó A,Zarba JJ,Blajman C,Varela MS,Martínez-Mesa J,Werutsky G,Barrios CH

更新日期：2016-02-01 00:00:00

abstract：INTRODUCTION:The purpose of this study was to evaluate whether diagnostic performance of breast magnetic resonance imaging (MRI) for detection of multifocality and multicentricity (MFMC) of breast cancer (BC) can be influenced by different histotypes or immunophenotypes in newly diagnosed patients with breast cancer. ...

journal_title：Clinical breast cancer

authors： Prochowski Iamurri A,Ponziani M,Macchini M,Fogante M,Pistelli M,De Lisa M,Berardi R,Giuseppetti GM

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND:Postmenopausal women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and the CORE (Continuing Outcomes Relevant to Evista) trial, a 4-year fol...

journal_title：Clinical breast cancer

authors： Vogel VG,Qu Y,Wong M,Mitchell B,Mershon JL

更新日期：2009-02-01 00:00:00

abstract：:Breast cancer is the second leading cause of cancer death in women, affecting 1.7 million patients every year worldwide. As a result of its heterogeneous nature, the genetic profile and associated clinical feature varies greatly among different breast cancer subtypes. With the advancement of molecular biology, our und...

journal_title：Clinical breast cancer

authors： Tang Y,Wang Y,Kiani MF,Wang B

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:Aromatase inhibitor therapy is often effective for breast cancer, yet it can be accompanied by musculoskeletal pain and stiffness. This prevalence assessment aimed to characterize a rheumatologist's view of frequency and clinical features, including associated disability, within a breast cancer clinic panel ...

journal_title：Clinical breast cancer

authors： Moxley G

更新日期：2010-04-01 00:00:00

abstract：BACKGROUND:Metastases to the brain occur in 10%-16% of patients with breast cancer, with incidence reportedly increasing. Historically, brain metastases (BM) have been treated with whole-brain radiation therapy (WBRT), but stereotactic radiosurgery (SRS) is an increasingly favored treatment option. In this study we use...

journal_title：Clinical breast cancer

authors： Mainwaring W,Bowers J,Pham N,Pezzi T,Shukla M,Bonnen M,Ludwig M

更新日期：2019-04-01 00:00:00

abstract：:Breast cancer is the most common cancer affecting women, causing 29% of all female cancers and afflicting 14% of all female cancer-related deaths worldwide. It remains a significant clinical, psychological, and financial burden. Exercise has been suggested to reduce cancer recurrence and cancer-related mortality from ...

journal_title：Clinical breast cancer

authors： Kapila AK,Hamdi M,Patel A

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:Intensive chemotherapy confers benefit to patients with high-risk early breast cancer (BC). We characterized the feasibility and toxicity profile of anthracycline-containing adjuvant chemotherapy (ACAC) in older women with early BC. PATIENTS AND METHODS:Available data from women who received ACAC for BC in ...

journal_title：Clinical breast cancer

authors： Karavasilis V,Papadimitriou C,Gogas H,Kouvatseas G,Pentheroudakis G,Koutras A,Christodoulou C,Bafaloukos D,Samantas E,Pisanidis N,Papakostas P,Aravantinos G,Karanikiotis C,Kosmidis P,Pectasides D,Dimopoulos MA,Fountzilas

更新日期：2016-08-01 00:00:00